GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma
2022 · Journal of Experimental & Clinical Cancer Research · 9 citations
https://doi.org/10.1186/s13046-022-02463-6
M
Matheus Sewastjanow‐Silva
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
34
Papers
569
Citations
8
h-index
6
i10-index
Matheus Sewastjanow‐Silva is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Esophageal Cancer Research and Treatment & Cancer Immunotherapy and Biomarkers. The author has an h-index of 8, co-authored 29 publications.
ORCID: 0000-0003-4804-1891Papers by this author
worksThree biomarkers ( <scp>HER2</scp> , <scp>PD‐L1</scp> , and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The <scp>MD Anderson Cancer Center</scp> experience
2024 · International Journal of Cancer · 3 citations
https://doi.org/10.1002/ijc.35090
DIAGNOSTIC VALUE OF THE REACTION AT THE BACILLUS CALMETTE-GUÉRIN VACCINATION SITE IN KAWASAKI DISEASE
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14282593
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat